Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4kappa antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4].
Molecular Weight:
(146.48 kDa)
Purity:
96.81
CAS Number:
[1660159-36-3]
Target:
ADC Antibody,Apoptosis,CD22
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted